Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping

Cardiovascular Toxicology

Volumn 9, Issue 4, 2009, Pages 201-210

  Piloto, Nuno ^a   Teixeira, Helena M ^b   Teixeira Lemos, Edite ^a   Parada, Belmiro ^a   Garrido, Patrícia ^a   Sereno, José ^a   Pinto, Rui ^c   Carvalho, Lina ^a   Costa, Elísio ^d,e   Belo, Luís ^e,f   Santos Silva, Alice ^e,f   Teixeira, Frederico ^a,e   Reis, Flávio ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b INSTITUTO NACIONAL DE MEDICINA LEGAL E CIÊNCIAS FORENSES   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cardiovascular and mortality risk; Chronic aerobic exercise; Doping; RhEPO

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOPING; ERYTHROCYTE COUNT; EXERCISE INTENSITY; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; HYPERVISCOSITY SYNDROME; MALE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OFF LABEL DRUG USE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION; SUDDEN DEATH; SYMPATHETIC TONE;

ANIMALS; CARDIOVASCULAR DISEASES; DOPING IN SPORTS; ERYTHROPOIETIN, RECOMBINANT; MALE; MODELS, ANIMAL; RATS; RATS, WISTAR; RISK FACTORS;

RATTUS; RATTUS NORVEGICUS;

EID: 71949111878     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-009-9054-2     Document Type: Article

References (31)

1. C Lacombe P Mayeux 2006 Biology of erythropoietin Haematologica 83 724 732
2. D Fliser FH Bahlmann H Haller 2006 EPO: Renoprotetion beyond anemia correction Pediatric Nephrology 21 1785 1789 10.1007/s00467-006-0284-2 16957890 (Pubitemid 44741154)
3. S Elliott 2008 Erythropoiesis-stimulating agents and other methods to enhance oxygen transport British Journal of Pharmacology 154 529 541 10.1038/bjp.2008.89 1:CAS:528:DC%2BD1cXmt1Kqtbc%3D 18362898 (Pubitemid 351744957)
4. F Lasne J de Ceaurriz 2000 Recombinant human erythropoietin in urine Nature 405 635 10.1038/35015164 1:CAS:528:DC%2BD3cXktlCju7k%3D 10864311
5. N Robinson P Mangin M Saugy 2003 Erythropoietin abuse in sports Sysmex Journal International 13 75 77
6. R Bento L Damasceno F Neto 2003 Eritropoietina recombinante humana no esporte: uma revisão Revista Brasileira de Medicina do Esporte 9 169 180 10.1590/S1517-86922003000300006
7. PJ Stohlawetz L Dzirlo N Hergovich E Lackner C Mensik HG Eichler E Kabrna K Geissler B Jilma 2000 Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans Blood 95 2983 2999 1:CAS:528:DC%2BD3cXivVaqs7s%3D 10779449
8. R Gareau M Audran RD Baynes CH Flowers A Duvallet L Senécal GR Brisson 1996 Erythropoietin abuse in athletes Nature 380 113 10.1038/380113a0 1:CAS:528:DyaK28Xhs1Gnsrw%3D 8600382
9. LA Thein JM Thein GL Landry 1995 Ergogenic aids Physical Therapy 75 426 439 1:STN:280:DyaK2M3kvFKltQ%3D%3D 7732086
10. JW Adamson D Vapnek 1991 Recombinant human erythropoietin to improve athletic performance The New England Journal of Medicine 324 698 699 1:STN:280:DyaK3M7jtlGjtA%3D%3D 1994258
11. F Reis L Rocha L Ponte T Alcobia L Almeida C Costa-Almeida F Teixeira 2005 Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats Life Science 77 2514 2528 10.1016/j.lfs.2005.01.032 1:CAS:528:DC%2BD2MXpslylu7k%3D (Pubitemid 41222325)
12. V Estepa S Ródenas MC Martín 2001 Optimización de un método para la determinación de la peroxidación lipídica en suero humano Anales de la Real Academia de Farmacia 67 1 17
13. IFF Benzie JJ Strain 1996 The ferric reducing ability of plasma (FRAP) as a measure of ''antioxidant power'': The FRAP assay Analytical Biochemistry 239 70 76 10.1006/abio.1996.0292 1:CAS:528:DyaK28XksFCmt7Y%3D 8660627 (Pubitemid 26256285)
14. A Cruz 2006 Resistência aeróbia e eritropoietina Goiânia 33 553 572
15. M Cazzola 2002 A global strategy for prevention and detection of blood doping with erythropoietin and related drugs Haematologica 85 561 563 (Pubitemid 30450933)
16. B Berglund G Birgegard P Hemmingsson 1988 Serum erythropoietin in cross country skiers Medicine and Science in Sports and Exercise 20 208 209 10.1249/00005768-198820020-00017 1:STN:280:DyaL1c3hs1Slsw%3D%3D 3367758
17. HJ Schwandt B Heyduck HC Gunga L Röcker 1991 Influence of prolonged physical exercise on the erythropoietin concentration in blood European Journal of Applied Physiology and Occupational Physiology 63 463 466 10.1007/BF00868079 1:STN:280:DyaK387htFCluw%3D%3D 1765060
18. J Gauthier 2001 Effets cardiovasculaires du dopage Annales de Cardiologie et d'Angeiologie 50293 8
19. A Torralbo JA Herrerro J Portolés A Fontanellas A Barrientos 1995 Activation of the sympathetic nervous system in hemodialyzed patients treated with erythropoietin Nephron 69 350 10.1159/000188491 1:STN:280: DyaK2M3nt1Oqsw%3D%3D 7753279
20. K Maiese F Li ZZ Chong 2005 New avenues of exploration for erythropoietin JAMA 293 90 95 10.1001/jama.293.1.90 1:CAS:528:DC%2BD2MXht1Gmtw%3D%3D 15632341 (Pubitemid 40066704)
21. NP Riksen DJ Hausenloy DM Yellon 2008 Erythropoietin: Ready for prime-time cardioprotection TiPS 29 258 267 1:CAS:528:DC%2BD1cXlslWqu7s%3D 18359096
22. R Latini M Brines F Fiordaliso 2008 Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Failure Reviews 13 415 423 10.1007/s10741-008-9084-z 1:CAS:528:DC%2BD1cXlvFaisLk%3D 18236153
23. CJ Parsa A Matsumoto J Kim RU Riel LS Pascal GB Walton RB Thompson JA Petrofski BH Annex JS Stamler WJ Koch 2003 A novel protective effect of erythropoietin in the infracted heart The Journal of Clinical Investigation 112 999 1007 1:CAS:528:DC%2BD3sXnvFGrsL0%3D 14523037
24. E Lipsic RG Schoemaker P van der Meer AA Voors DJ van Veldhuisen WH van Gilst 2006 Protective effects of erythropoietin in cardiac ischemia Journal of the American College of Cardiology 48 2161 2167 10.1016/j.jacc.2006.08.031 1:CAS:528:DC%2BD28Xht12ks77E 17161240 (Pubitemid 44855436)
25. W Tao F Wen H Zhang G Liu 2009 The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral plasy Brain and Development 31 200 207 10.1016/j.braindev.2008.06.011 18715729
26. P Katavenin K Tungsanga S Eiam-Ong M Nagaku 2007 Antioxidative effects of erythropoietin Kidney International 72 S10 S15 10.1038/sj.ki.5002482 (Pubitemid 47609057)
27. K Maiese ZZ Chong J Hou YC Shang 2008 Erythropoietin and oxidative stress Current Neurovascular Research 5 125 142 10.2174/156720208784310231 1:CAS:528:DC%2BD1cXntV2rs7o%3D 18473829 (Pubitemid 351838578)
28. P Ghezzi M Brines 2004 Erythropoietin as an antiapoptotic, tissue-protective cytokine Cell Death and Differentiation 11 S37 S44 10.1038/sj.cdd.4401450 1:CAS:528:DC%2BD2cXlsFelu78%3D 15243580 (Pubitemid 39136797)
29. AS Manolis S Tzeism K Triantafyllou J Michaelidis I Pyrros N Sakellaris A Kranidis H Melita 2005 Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects Current Drug Targets-Cardiovascular and Haematological Disorders 5 355 375 10.2174/156800605774370326 1:CAS:528:DC%2BD2MXhtFyhtr3F 16248829 (Pubitemid 41631546)
30. DL Regidor JD Kopple CP Kovesdy RD Kilpatrick CJ McAllister J Aronovitz S Greenland K Kalantar-Zadeh 2006 Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients Journal of the American Society of Nephrology 17 1181 1191 10.1681/ASN.2005090997 1:CAS:528:DC%2BD28XjvFSqtrY%3D 16565261
31. KF Wagner DM Katschinski J Hasegawa D Schumacher B Meller U Gembruch U Schramm W Jelkmann M Gassmann J Fandrey 2001 Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin Blood 97 536 542 10.1182/blood.V97.2.536 1:CAS:528: DC%2BD3MXlvF2htg%3D%3D 11154234 (Pubitemid 32060342)